Validation of 2 depression screening tools in dialysis patients

Suzanne Watnick, Pei Li Wang, Theresa Demadura, Linda Ganzini

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

Background: Depression is the most common psychiatric disorder in long-term dialysis patients and is a risk factor for morbidity and mortality. An efficient and valid method of diagnosing depression might facilitate recognition and treatment. We sought to validate 2 depression assessment tools, the 21-question Beck Depression Inventory (BDI) and the 9-question Patient Health Questionnaire (PHQ-9), in a dialysis population. Methods: We surveyed patients who had received dialysis for at least 90 days in Portland, OR. We excluded patients with dementia, delirium, or a history of major psychiatric disorders other than depression. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, a gold-standard measure for depression, was administered by trained psychologists within 2 weeks of the BDI and PHQ-9. Results: Of 62 enrolled subjects, 16 were diagnosed with a depressive disorder, including 12 patients (19%) with major depression, 3 patients with dysthymia, and 1 patient with minor depression. Optimal BDI and PHQ-9 cutoff values for depressive disorders combined was 16 or greater and 10 or greater, respectively. Sensitivities were 91% and 92%, specificities were 86% and 92%, positive predictive values were 59% and 71%, and negative predictive values were both 98%, with κ values of 0.65 and 0.75, respectively. The difference between the 2 receiver operating characteristic curves was not statistically significant (P > 0.9). Conclusion: Our results validate the PHQ-9 and revalidate the BDI against a gold-standard measure for depressive disorders in the dialysis population. Both tools performed equally well. Because depression is prevalent, readily diagnosed, and associated with poor outcomes, screening by means of short and valid measurement tools may lead to better diagnosis and treatment of this modifiable risk factor. This may lead to improved clinical outcomes in dialysis patients.

Original languageEnglish (US)
Pages (from-to)919-924
Number of pages6
JournalAmerican Journal of Kidney Diseases
Volume46
Issue number5
DOIs
StatePublished - Nov 2005

Fingerprint

Dialysis
Depression
Depressive Disorder
Equipment and Supplies
Gold
Psychiatry
Delirium
ROC Curve
Diagnostic and Statistical Manual of Mental Disorders
Population
Dementia
Interviews
Psychology
Morbidity
Mortality
Health
Therapeutics

Keywords

  • Depression
  • Dialysis
  • Screening

ASJC Scopus subject areas

  • Nephrology

Cite this

Validation of 2 depression screening tools in dialysis patients. / Watnick, Suzanne; Wang, Pei Li; Demadura, Theresa; Ganzini, Linda.

In: American Journal of Kidney Diseases, Vol. 46, No. 5, 11.2005, p. 919-924.

Research output: Contribution to journalArticle

Watnick, Suzanne ; Wang, Pei Li ; Demadura, Theresa ; Ganzini, Linda. / Validation of 2 depression screening tools in dialysis patients. In: American Journal of Kidney Diseases. 2005 ; Vol. 46, No. 5. pp. 919-924.
@article{5bed31b61d4141608b5b5107b39779f0,
title = "Validation of 2 depression screening tools in dialysis patients",
abstract = "Background: Depression is the most common psychiatric disorder in long-term dialysis patients and is a risk factor for morbidity and mortality. An efficient and valid method of diagnosing depression might facilitate recognition and treatment. We sought to validate 2 depression assessment tools, the 21-question Beck Depression Inventory (BDI) and the 9-question Patient Health Questionnaire (PHQ-9), in a dialysis population. Methods: We surveyed patients who had received dialysis for at least 90 days in Portland, OR. We excluded patients with dementia, delirium, or a history of major psychiatric disorders other than depression. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, a gold-standard measure for depression, was administered by trained psychologists within 2 weeks of the BDI and PHQ-9. Results: Of 62 enrolled subjects, 16 were diagnosed with a depressive disorder, including 12 patients (19{\%}) with major depression, 3 patients with dysthymia, and 1 patient with minor depression. Optimal BDI and PHQ-9 cutoff values for depressive disorders combined was 16 or greater and 10 or greater, respectively. Sensitivities were 91{\%} and 92{\%}, specificities were 86{\%} and 92{\%}, positive predictive values were 59{\%} and 71{\%}, and negative predictive values were both 98{\%}, with κ values of 0.65 and 0.75, respectively. The difference between the 2 receiver operating characteristic curves was not statistically significant (P > 0.9). Conclusion: Our results validate the PHQ-9 and revalidate the BDI against a gold-standard measure for depressive disorders in the dialysis population. Both tools performed equally well. Because depression is prevalent, readily diagnosed, and associated with poor outcomes, screening by means of short and valid measurement tools may lead to better diagnosis and treatment of this modifiable risk factor. This may lead to improved clinical outcomes in dialysis patients.",
keywords = "Depression, Dialysis, Screening",
author = "Suzanne Watnick and Wang, {Pei Li} and Theresa Demadura and Linda Ganzini",
year = "2005",
month = "11",
doi = "10.1053/j.ajkd.2005.08.006",
language = "English (US)",
volume = "46",
pages = "919--924",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Validation of 2 depression screening tools in dialysis patients

AU - Watnick, Suzanne

AU - Wang, Pei Li

AU - Demadura, Theresa

AU - Ganzini, Linda

PY - 2005/11

Y1 - 2005/11

N2 - Background: Depression is the most common psychiatric disorder in long-term dialysis patients and is a risk factor for morbidity and mortality. An efficient and valid method of diagnosing depression might facilitate recognition and treatment. We sought to validate 2 depression assessment tools, the 21-question Beck Depression Inventory (BDI) and the 9-question Patient Health Questionnaire (PHQ-9), in a dialysis population. Methods: We surveyed patients who had received dialysis for at least 90 days in Portland, OR. We excluded patients with dementia, delirium, or a history of major psychiatric disorders other than depression. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, a gold-standard measure for depression, was administered by trained psychologists within 2 weeks of the BDI and PHQ-9. Results: Of 62 enrolled subjects, 16 were diagnosed with a depressive disorder, including 12 patients (19%) with major depression, 3 patients with dysthymia, and 1 patient with minor depression. Optimal BDI and PHQ-9 cutoff values for depressive disorders combined was 16 or greater and 10 or greater, respectively. Sensitivities were 91% and 92%, specificities were 86% and 92%, positive predictive values were 59% and 71%, and negative predictive values were both 98%, with κ values of 0.65 and 0.75, respectively. The difference between the 2 receiver operating characteristic curves was not statistically significant (P > 0.9). Conclusion: Our results validate the PHQ-9 and revalidate the BDI against a gold-standard measure for depressive disorders in the dialysis population. Both tools performed equally well. Because depression is prevalent, readily diagnosed, and associated with poor outcomes, screening by means of short and valid measurement tools may lead to better diagnosis and treatment of this modifiable risk factor. This may lead to improved clinical outcomes in dialysis patients.

AB - Background: Depression is the most common psychiatric disorder in long-term dialysis patients and is a risk factor for morbidity and mortality. An efficient and valid method of diagnosing depression might facilitate recognition and treatment. We sought to validate 2 depression assessment tools, the 21-question Beck Depression Inventory (BDI) and the 9-question Patient Health Questionnaire (PHQ-9), in a dialysis population. Methods: We surveyed patients who had received dialysis for at least 90 days in Portland, OR. We excluded patients with dementia, delirium, or a history of major psychiatric disorders other than depression. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, a gold-standard measure for depression, was administered by trained psychologists within 2 weeks of the BDI and PHQ-9. Results: Of 62 enrolled subjects, 16 were diagnosed with a depressive disorder, including 12 patients (19%) with major depression, 3 patients with dysthymia, and 1 patient with minor depression. Optimal BDI and PHQ-9 cutoff values for depressive disorders combined was 16 or greater and 10 or greater, respectively. Sensitivities were 91% and 92%, specificities were 86% and 92%, positive predictive values were 59% and 71%, and negative predictive values were both 98%, with κ values of 0.65 and 0.75, respectively. The difference between the 2 receiver operating characteristic curves was not statistically significant (P > 0.9). Conclusion: Our results validate the PHQ-9 and revalidate the BDI against a gold-standard measure for depressive disorders in the dialysis population. Both tools performed equally well. Because depression is prevalent, readily diagnosed, and associated with poor outcomes, screening by means of short and valid measurement tools may lead to better diagnosis and treatment of this modifiable risk factor. This may lead to improved clinical outcomes in dialysis patients.

KW - Depression

KW - Dialysis

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=27144516176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144516176&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2005.08.006

DO - 10.1053/j.ajkd.2005.08.006

M3 - Article

C2 - 16253733

AN - SCOPUS:27144516176

VL - 46

SP - 919

EP - 924

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 5

ER -